

# Aaron Mansfield

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6933252/publications.pdf>

Version: 2024-02-01

187  
papers

11,655  
citations

66343

42  
h-index

32842

100  
g-index

193  
all docs

193  
docs citations

193  
times ranked

17071  
citing authors

| #  | ARTICLE   | IF    | CITATIONS |
|----|---|-------|-----------|
| 1  | First-Line Atezolizumab plus Chemotherapy in Extensive-Stage Small-Cell Lung Cancer. <i>New England Journal of Medicine</i> , 2018, 379, 2220-2229.   | 27.0  | 2,228     |
| 2  | Detection and localization of surgically resectable cancers with a multi-analyte blood test. <i>Science</i> , 2018, 359, 926-930.   | 12.6  | 1,872     |
| 3  | First-line nivolumab plus ipilimumab in unresectable malignant pleural mesothelioma (CheckMate 743): a multicentre, randomised, open-label, phase 3 trial. <i>Lancet</i> , 2021, 397, 375-386.  | 13.7  | 638       |
| 4  | Integrating genomic features for non-invasive early lung cancer detection. <i>Nature</i> , 2020, 580, 245-251.  | 27.8  | 379       |
| 5  | PD-1 Restrains Radiotherapy-Induced Abscopal Effect. <i>Cancer Immunology Research</i> , 2015, 3, 610-619.  | 3.4   | 327       |
| 6  | Updated Overall Survival and PD-L1 Subgroup Analysis of Patients With Extensive-Stage Small-Cell Lung Cancer Treated With Atezolizumab, Carboplatin, and Etoposide (IMpower133). <i>Journal of Clinical Oncology</i> , 2021, 39, 619-630. | 1.6   | 317       |
| 7  | Mesothelioma: Scientific clues for prevention, diagnosis, and therapy. <i>Ca-A Cancer Journal for Clinicians</i> , 2019, 69, 402-429.   | 329.8 | 306       |
| 8  | Temporal and spatial discordance of programmed cell death-ligand 1 expression and lymphocyte tumor infiltration between paired primary lesions and brain metastases in lung cancer. <i>Annals of Oncology</i> , 2016, 27, 1953-1958.      | 1.2   | 289       |
| 9  | Representation of Minorities and Women in Oncology Clinical Trials: Review of the Past 14 Years. <i>Journal of Oncology Practice</i> , 2018, 14, e1-e10.  | 2.5   | 245       |
| 10 | Pralsetinib for RET fusion-positive non-small-cell lung cancer (ARROW): a multi-cohort, open-label, phase 1/2 study. <i>Lancet Oncology</i> , 2021, 22, 959-969.  | 10.7  | 222       |
| 11 | B7-H1 Expression in Malignant Pleural Mesothelioma is Associated with Sarcomatoid Histology and Poor Prognosis. <i>Journal of Thoracic Oncology</i> , 2014, 9, 1036-1040.   | 1.1   | 208       |
| 12 | Current Diagnosis and Management of Small-Cell Lung Cancer. <i>Mayo Clinic Proceedings</i> , 2019, 94, 1599-1622.   | 3.0   | 175       |
| 13 | Nomograms Predict Overall Survival for Patients with Small-Cell Lung Cancer Incorporating Pretreatment Peripheral Blood Markers. <i>Journal of Thoracic Oncology</i> , 2015, 10, 1213-1220.   | 1.1   | 122       |
| 14 | Heterogeneity of Programmed Cell Death Ligand 1 Expression in Multifocal Lung Cancer. <i>Clinical Cancer Research</i> , 2016, 22, 2177-2182.  | 7.0   | 119       |
| 15 | Predictors of active cancer thromboembolic outcomes: validation of the Khorana score among patients with lung cancer. <i>Journal of Thrombosis and Haemostasis</i> , 2016, 14, 1773-1778.   | 3.8   | 113       |
| 16 | CX3CR1 identifies PD-1 therapy-responsive CD8+ T cells that withstand chemotherapy during cancer chemoimmunotherapy. <i>JCI Insight</i> , 2018, 3, .  | 5.0   | 106       |
| 17 | Safety and patient-reported outcomes of atezolizumab, carboplatin, and etoposide in extensive-stage small-cell lung cancer (IMpower133): a randomized phase I/III trial. <i>Annals of Oncology</i> , 2020, 31, 310-317.                   | 1.2   | 105       |
| 18 | Phase II Study of AZD4547 in Patients With Tumors Harboring Aberrations in the FGFR Pathway: Results From the NCI-MATCH Trial (EAY131) Subprotocol W. <i>Journal of Clinical Oncology</i> , 2020, 38, 2407-2417.                          | 1.6   | 102       |

| #  | ARTICLE   | IF  | CITATIONS |
|----|---|-----|-----------|
| 19 | First-line nivolumab plus ipilimumab versus chemotherapy in patients with unresectable malignant pleural mesothelioma: 3-year outcomes from CheckMate 743. <i>Annals of Oncology</i> , 2022, 33, 488-499.   | 1.2 | 99        |
| 20 | Survival of cutaneous melanoma based on sex, age, and stage in the United States, 1992â€“2011. <i>Cancer Medicine</i> , 2017, 6, 2203-2212.   | 2.8 | 98        |
| 21 | Predictors Of Cancer Associated Thrombosis. <i>Blood</i> , 2013, 122, 3616-3616.  | 1.4 | 93        |
| 22 | Neoantigenic Potential of Complex Chromosomal Rearrangements in Mesothelioma. <i>Journal of Thoracic Oncology</i> , 2019, 14, 276-287.  | 1.1 | 92        |
| 23 | Simultaneous Foxp3 and IDO expression is associated with sentinel lymph node metastases in breast cancer. <i>BMC Cancer</i> , 2009, 9, 231.   | 2.6 | 91        |
| 24 | Current and Future Management of Malignant Mesothelioma: A Consensus Report from the National Cancer Institute Thoracic Malignancy Steering Committee, International Association for the Study of Lung Cancer, and Mesothelioma Applied Research Foundation. <i>Journal of Thoracic Oncology</i> , 2018, 13, 1655-1667. | 1.1 | 85        |
| 25 | Safety, Tolerability, and Preliminary Activity of LB-100, an Inhibitor of Protein Phosphatase 2A, in Patients with Relapsed Solid Tumors: An Open-Label, Dose Escalation, First-in-Human, Phase I Trial. <i>Clinical Cancer Research</i> , 2017, 23, 3277-3284.   | 7.0 | 82        |
| 26 | An Exploratory Analysis of Real-World End Points for Assessing Outcomes Among Immunotherapy-Treated Patients With Advanced Nonâ€“Small-Cell Lung Cancer. <i>JCO Clinical Cancer Informatics</i> , 2019, 3, 1-15.  | 2.1 | 81        |
| 27 | Sex Differences in Tolerability to Anti-Programmed Cell Death Protein 1 Therapy in Patients with Metastatic Melanoma and Non-Small Cell Lung Cancer: Are We All Equal?. <i>Oncologist</i> , 2019, 24, e1148-e1155.  | 3.7 | 81        |
| 28 | ADAM10 and ADAM17 cleave PD-L1 to mediate PD-(L)1 inhibitor resistance. <i>Oncolmmunology</i> , 2020, 9, 1744980.   | 4.6 | 77        |
| 29 | Immune Cell Infiltration May Be a Key Determinant of Long-Term Survival in Small Cell Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2019, 14, 1286-1295.   | 1.1 | 75        |
| 30 | Contraction of T cell richness in lung cancer brain metastases. <i>Scientific Reports</i> , 2018, 8, 2171.  | 3.3 | 74        |
| 31 | Normal ageing is associated with an increase in Th2 cells, MCP-1 (CCL1) and RANTES (CCL5), with differences in sCD40L and PDGF-AA between sexes. <i>Clinical and Experimental Immunology</i> , 2012, 170, 186-193.  | 2.6 | 70        |
| 32 | T cell Bim levels reflect responses to antiâ€“PD-1 cancer therapy. <i>JCI Insight</i> , 2016, 1, .  | 5.0 | 68        |
| 33 | Progress in the Management of Malignant Pleuralâ€Mesothelioma in 2017. <i>Journal of Thoracic Oncology</i> , 2018, 13, 606-623.   | 1.1 | 67        |
| 34 | Immune cell quantitation in normal breast tissue lobules with and without lobulitis. <i>Breast Cancer Research and Treatment</i> , 2014, 144, 539-549.  | 2.5 | 65        |
| 35 | The Role of Vascular Endothelial Growth Factor in the Pathogenesis, Diagnosis and Treatment of Malignant Pleural Effusion. <i>Current Oncology Reports</i> , 2013, 15, 207-216.   | 4.0 | 61        |
| 36 | Chromoplectic TPM3â€“ALK rearrangement in a patient with inflammatory myofibroblastic tumor who responded to ceritinib after progression on crizotinib. <i>Annals of Oncology</i> , 2016, 27, 2111-2117.  | 1.2 | 57        |

| #  | ARTICLE   | IF  | CITATIONS |
|----|---|-----|-----------|
| 37 | Experience with precision genomics and tumor board, indicates frequent target identification, but barriers to delivery. <i>Oncotarget</i> , 2017, 8, 27145-27154.   | 1.8 | 55        |
| 38 | Using Genomics to Differentiate Multiple Primaries From Metastatic Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2019, 14, 1567-1582.  | 1.1 | 55        |
| 39 | Detection of Nonreciprocal/Reciprocal ALK Translocation as Poor Predictive Marker in Patients With First-Line Crizotinib-Treated ALK-Rearranged NSCLC. <i>Journal of Thoracic Oncology</i> , 2020, 15, 1027-1036.   | 1.1 | 55        |
| 40 | Regional immunity in melanoma: immunosuppressive changes precede nodal metastasis. <i>Modern Pathology</i> , 2011, 24, 487-494.   | 5.5 | 51        |
| 41 | S768I Mutation in EGFR in Patients with Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2016, 11, 1798-1801.   | 1.1 | 50        |
| 42 | Phase I dose escalation study of the PKC $\delta$ inhibitor aurothiomalate for advanced non-small-cell lung cancer, ovarian cancer, and pancreatic cancer. <i>Anti-Cancer Drugs</i> , 2013, 24, 1079-1083.  | 1.4 | 47        |
| 43 | Systematic review of response rates of sarcomatoid malignant pleural mesotheliomas in clinical trials. <i>Lung Cancer</i> , 2014, 86, 133-136.  | 2.0 | 45        |
| 44 | Medical and Surgical Care of Patients With Mesothelioma and Their Relatives Carrying Germline BAP1 Mutations. <i>Journal of Thoracic Oncology</i> , 2022, 17, 873-889.  | 1.1 | 44        |
| 45 | Metastasis to sentinel lymph nodes in breast cancer is associated with maturation arrest of dendritic cells and poor co-localization of dendritic cells and CD8+ T cells. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2011, 459, 391-398. | 2.8 | 41        |
| 46 | Early venous thromboembolic events are associated with worse prognosis in patients with lung cancer. <i>Lung Cancer</i> , 2014, 86, 358-362.  | 2.0 | 40        |
| 47 | Tumor Mutational Burden From Tumor-Only Sequencing Compared With Germline Subtraction From Paired Tumor and Normal Specimens. <i>JAMA Network Open</i> , 2020, 3, e200202.  | 5.9 | 40        |
| 48 | The Mayo Clinic experience with the use of kinase inhibitors, ipilimumab, bevacizumab, and local therapies in the treatment of metastatic uveal melanoma. <i>Melanoma Research</i> , 2015, 25, 59-63.   | 1.2 | 38        |
| 49 | Comparison of Risk Stratification Models to Predict Recurrence and Survival in Pleuropulmonary Solitary Fibrous Tumor. <i>Journal of Thoracic Oncology</i> , 2018, 13, 1349-1362.   | 1.1 | 38        |
| 50 | The immunomodulatory effects of bevacizumab on systemic immunity in patients with metastatic melanoma. <i>Oncolmmunology</i> , 2013, 2, e24436.   | 4.6 | 37        |
| 51 | Targeting B7-H1 (PD-L1) sensitizes cancer cells to chemotherapy. <i>Heliyon</i> , 2018, 4, e01039.  | 3.2 | 37        |
| 52 | B7-H1 antibodies lose antitumor activity due to activation of p38 MAPK that leads to apoptosis of tumor-reactive CD8+ T cells. <i>Scientific Reports</i> , 2016, 6, 36722.  | 3.3 | 36        |
| 53 | Advances in the Treatment of Non-small Cell Lung Cancer: Focus on Nivolumab, Pembrolizumab, and Atezolizumab. <i>BioDrugs</i> , 2016, 30, 397-405.  | 4.6 | 36        |
| 54 | Meta-analysis on anticoagulation and prevention of thrombosis and mortality among patients with lung cancer. <i>Thrombosis Research</i> , 2017, 154, 28-34.   | 1.7 | 36        |

| #  | ARTICLE   | IF  | CITATIONS |
|----|---|-----|-----------|
| 55 | Understanding heterogeneous tumor microenvironment in metastatic melanoma. <i>PLoS ONE</i> , 2019, 14, e0216485.  | 2.5 | 36        |
| 56 | Characterization of Comorbidities Limiting the Recruitment of Patients in Early Phase Clinical Trials. <i>Oncologist</i> , 2019, 24, 96-102.  | 3.7 | 35        |
| 57 | Comparison of Fluorescence In Situ Hybridization (FISH) and Dual-ISH (DISH) in the Determination of HER2 Status in Breast Cancer. <i>American Journal of Clinical Pathology</i> , 2013, 139, 144-150.                                   | 0.7 | 33        |
| 58 | Development and External Validation of a Prognostic Nomogram for Metastatic Uveal Melanoma. <i>PLoS ONE</i> , 2015, 10, e0120181.   | 2.5 | 33        |
| 59 | CpG-induced antitumor immunity requires IL-12 in expansion of effector cells and down-regulation of PD-1. <i>Oncotarget</i> , 2016, 7, 70223-70231.   | 1.8 | 33        |
| 60 | Therapeutic plasma exchange clears circulating soluble PD-L1 and PD-L1-positive extracellular vesicles. <i>Journal of Clinical Investigation</i> , 2020, 130, e001113.  |     | 32        |
| 61 | Outcomes With Pembrolizumab Monotherapy in Patients With Programmed Death-Ligand 1-Positive NSCLC With Brain Metastases: Pooled Analysis of KEYNOTE-001, 010, 024, and 042. <i>JTO Clinical and Research Reports</i> , 2021, 2, 100205. | 1.1 | 32        |
| 62 | Concurrent MCL1 and JUN amplification in pseudomyxoma peritonei: a comprehensive genetic profiling and survival analysis. <i>Journal of Human Genetics</i> , 2014, 59, 124-128.   | 2.3 | 31        |
| 63 | Pregnancy-associated plasma protein-A expression in human breast cancer. <i>Growth Hormone and IGF Research</i> , 2014, 24, 264-267.  | 1.1 | 31        |
| 64 | A phase I study of the safety and tolerability of VLX600, an Iron Chelator, in patients with refractory advanced solid tumors. <i>Investigational New Drugs</i> , 2019, 37, 684-692.  | 2.6 | 30        |
| 65 | A Population-based Study of Immunotherapy-related Toxicities in Lung Cancer. <i>Clinical Lung Cancer</i> , 2020, 21, 421-427.e2.  | 2.6 | 30        |
| 66 | Asphyxiation with a Fentanyl Patch. <i>Case Reports in Oncology</i> , 2013, 6, 242-244.   | 0.7 | 27        |
| 67 | Temporal and spatial heterogeneity of programmed cell death 1-Ligand 1 expression in malignant mesothelioma. <i>Oncolmmunology</i> , 2017, 6, e1356146.   | 4.6 | 27        |
| 68 | A phase I/II study of rovalpituzumab tesirine in delta-like 3-expressing advanced solid tumors. <i>Npj Precision Oncology</i> , 2021, 5, 74.  | 5.4 | 27        |
| 69 | Management of Multifocal Lung Cancer: Results of a Survey. <i>Journal of Thoracic Oncology</i> , 2017, 12, 1398-1402.   | 1.1 | 27        |
| 70 | Primary venous thromboembolism prophylaxis in patients with solid tumors: a meta-analysis. <i>Journal of Thrombosis and Thrombolysis</i> , 2014, 38, 241-249.   | 2.1 | 26        |
| 71 | HLA class-I and class-II restricted neoantigen loads predict overall survival in breast cancer. <i>Oncolmmunology</i> , 2020, 9, 1744947.   | 4.6 | 26        |
| 72 | New Era for Malignant Pleural Mesothelioma: Updates on Therapeutic Options. <i>Journal of Clinical Oncology</i> , 2022, 40, 681-692.  | 1.6 | 26        |

| #  | ARTICLE   | IF  | CITATIONS |
|----|---|-----|-----------|
| 73 | NKG7 Is a T-cellâ€™Intrinsic Therapeutic Target for Improving Antitumor Cytotoxicity and Cancer Immunotherapy. <i>Cancer Immunology Research</i> , 2022, 10, 162-181.   | 3.4 | 26        |
| 74 | Evidence of Th2 polarization of the sentinel lymph node (SLN) in melanoma. <i>Oncolmmunology</i> , 2015, 4, e1026504.   | 4.6 | 25        |
| 75 | DARPP-32 and t-DARPP promote non-small cell lung cancer growth through regulation of IKKÎ±-dependent cell migration. <i>Communications Biology</i> , 2018, 1, 43.   | 4.4 | 25        |
| 76 | Prospective Immunophenotyping of CD8+ T Cells and Associated Clinical Outcomes of Patients With Oligometastatic Prostate Cancer Treated With Metastasis-Directed SBRT. <i>International Journal of Radiation Oncology Biology Physics</i> , 2019, 103, 229-240. | 0.8 | 24        |
| 77 | Mayo Clinic Experience With Very Rare Exocrine Pancreatic Neoplasms. <i>Pancreas</i> , 2010, 39, 972-975.   | 1.1 | 23        |
| 78 | The Effect of Hepatic Impairment on Outcomes in Phase I Clinical Trials in Cancer Subjects. <i>Clinical Cancer Research</i> , 2016, 22, 5472-5479.  | 7.0 | 23        |
| 79 | Nomogram prediction of overall survival for patients with non-small-cell lung cancer incorporating pretreatment peripheral blood markersâ€™. <i>European Journal of Cardio-thoracic Surgery</i> , 2018, 53, 1214-1222.  | 1.4 | 23        |
| 80 | Chromosomal rearrangements and their neoantigenic potential in mesothelioma. <i>Translational Lung Cancer Research</i> , 2020, 9, S92-S99.  | 2.8 | 23        |
| 81 | Investigation of efficacy and acquired resistance for EGFR-TKI plus bevacizumab as first-line treatment in patients with EGFR sensitive mutant non-small cell lung cancer in a Real world population. <i>Lung Cancer</i> , 2020, 141, 82-88.                    | 2.0 | 23        |
| 82 | Implications of Programmed Cell Death 1 Ligand 1 Heterogeneity in the Selection of Patients With Nonâ€™Small Cell Lung Cancer to Receive Immunotherapy. <i>Clinical Pharmacology and Therapeutics</i> , 2016, 100, 220-222.                                     | 4.7 | 22        |
| 83 | First-in-human evaluation of the novel mitochondrial complex I inhibitor ASP4132 for treatment of cancer. <i>Investigational New Drugs</i> , 2021, 39, 1348-1356.   | 2.6 | 22        |
| 84 | A pilot study of Pan-FGFR inhibitor ponatinib in patients with FGFR-altered advanced cholangiocarcinoma. <i>Investigational New Drugs</i> , 2022, 40, 134-141.  | 2.6 | 21        |
| 85 | Novel therapeutics for the treatment of metastatic melanoma. <i>Future Oncology</i> , 2009, 5, 543-557.   | 2.4 | 20        |
| 86 | Skin Cancer Surveillance and Malignancies of the Skin in a Community-Dwelling Cohort of Patients With Newly Diagnosed Chronic Lymphocytic Leukemia. <i>Journal of Oncology Practice</i> , 2014, 10, e1-e4.  | 2.5 | 19        |
| 87 | Influence of Sociodemographic Factors on Treatment Decisions in Nonâ€™Small-Cell Lung Cancer. <i>Clinical Lung Cancer</i> , 2020, 21, e115-e129.  | 2.6 | 19        |
| 88 | Resectable pancreatic small cell carcinoma. <i>Rare Tumors</i> , 2011, 3, 13-17.  | 0.6 | 18        |
| 89 | Regional lymphatic immunity in melanoma. <i>Melanoma Research</i> , 2012, 22, 9-18.   | 1.2 | 18        |
| 90 | A Predictive Tool to Estimate the Risk of Axillary Metastases in Breast Cancer Patients with Negative Axillary Ultrasound. <i>Annals of Surgical Oncology</i> , 2014, 21, 2229-2236.  | 1.5 | 18        |

| #   | ARTICLE  | IF  | CITATIONS |
|-----|--|-----|-----------|
| 91  | Clinical impact of uncommon epidermal growth factor receptor exon 19 insertion-deletion variants on epidermal growth factor receptor-tyrosine kinase inhibitor efficacy in non-small-cell lung cancer. <i>European Journal of Cancer</i> , 2020, 141, 199-208.   | 2.8 | 18        |
| 92  | Crizotinib in patients with tumors harboring ALK or ROS1 rearrangements in the NCI-MATCH trial. <i>Npj Precision Oncology</i> , 2022, 6, 13.   | 5.4 | 18        |
| 93  | Pulmonary sarcomatoid carcinoma—a new hope. <i>Annals of Oncology</i> , 2017, 28, 1417-1418.   | 1.2 | 17        |
| 94  | Inflation of tumor mutation burden by tumor-only sequencing in under-represented groups. <i>Npj Precision Oncology</i> , 2021, 5, 22.  | 5.4 | 17        |
| 95  | Angiomatoid fibrous histiocytoma in a 25-year-old male. <i>Rare Tumors</i> , 2010, 2, 54-56.   | 0.6 | 16        |
| 96  | Prospective evaluation of protein C and factor VIII in prediction of cancer-associated thrombosis. <i>Thrombosis Research</i> , 2015, 136, 1120-1125.  | 1.7 | 16        |
| 97  | Expression of delta-like protein 3 is reproducibly present in a subset of small cell lung carcinomas and pulmonary carcinoid tumors. <i>Lung Cancer</i> , 2019, 135, 73-79.  | 2.0 | 16        |
| 98  | Clinical activity of the RET inhibitor pralsetinib (BLU-667) in patients with <i>RET</i> fusion–positive solid tumors.. <i>Journal of Clinical Oncology</i> , 2021, 39, 467-467.   | 1.6 | 16        |
| 99  | Radiologic Considerations and Standardization of Malignant Pleural Mesothelioma Imaging Within Clinical Trials: Consensus Statement from the NCI Thoracic Malignancy Steering Committee – International Association for the Study of Lung Cancer – Mesothelioma Applied Research Foundation Clinical Trials Planning Meeting. <i>Journal of Thoracic Oncology</i> , 2019, 14, 1718-1731. | 1.1 | 15        |
| 100 | Osimertinib-Induced Cardiomyopathy. <i>JACC: Case Reports</i> , 2020, 2, 641-645.  | 0.6 | 15        |
| 101 | The presence of sinusoidal CD163+ macrophages in lymph nodes is associated with favorable nodal status in patients with breast cancer. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2012, 461, 639-646.   | 2.8 | 14        |
| 102 | DNA methylation and RNA expression profiles in lung adenocarcinomas of never-smokers. <i>Cancer Genetics</i> , 2015, 208, 253-260.   | 0.4 | 14        |
| 103 | c-Met expression and MET amplification in malignant pleural mesothelioma. <i>Annals of Diagnostic Pathology</i> , 2016, 23, 1-7.   | 1.3 | 14        |
| 104 | Impact of delaying initiation of anaplastic lymphoma kinase inhibitor treatment on survival in patients with advanced non-small-cell lung cancer. <i>Lung Cancer</i> , 2020, 143, 86-92.   | 2.0 | 14        |
| 105 | Checkmate 743: A phase 3, randomized, open-label trial of nivolumab (nivo) plus ipilimumab (ipi) vs pemetrexed plus cisplatin or carboplatin as first-line therapy in unresectable pleural mesothelioma.. <i>Journal of Clinical Oncology</i> , 2017, 35, TPS8581-TPS8581.   | 1.6 | 14        |
| 106 | BRCA1/MAD2L1 Deficiency Disrupts the Spindle Assembly Checkpoint to Confer Vinorelbine Resistance in Mesothelioma. <i>Molecular Cancer Therapeutics</i> , 2021, 20, 379-388.   | 4.1 | 13        |
| 107 | Up-regulation of pro-angiogenic factors and establishment of tolerance in malignant pleural effusions. <i>Lung Cancer</i> , 2013, 82, 63-68.   | 2.0 | 12        |
| 108 | Feasibility and Acceptability of a Dignity Therapy/Life Plan Intervention for Patients With Advanced Cancer. <i>Oncology Nursing Forum</i> , 2017, 44, E194-E202.  | 1.2 | 12        |

| #   | ARTICLE   | IF  | CITATIONS |
|-----|---|-----|-----------|
| 109 | Incidence of major hemorrhage after aggressive image-guided liver mass biopsy in the era of individualized medicine. <i>Abdominal Radiology</i> , 2019, 44, 2067-2073.  | 2.1 | 12        |
| 110 | Bim and soluble PD-L1 (sPD-L1) as predictive biomarkers of response to anti-PD-1 therapy in patients with melanoma and lung carcinoma.. <i>Journal of Clinical Oncology</i> , 2017, 35, 11534-11534.  | 1.6 | 12        |
| 111 | Identification and Development of a Lung Adenocarcinoma PDX Model With STRN-ALK Fusion. <i>Clinical Lung Cancer</i> , 2019, 20, e142-e147.  | 2.6 | 11        |
| 112 | Delta-Like Protein 3 Expression and Targeting in Merkel Cell Carcinoma. <i>Oncologist</i> , 2020, 25, 810-817.  | 3.7 | 11        |
| 113 | A Phase Ib/II Study of Pepinemab in Combination with Avelumab in Advanced Nonâ€“Small Cell Lung Cancer. <i>Clinical Cancer Research</i> , 2021, 27, 3630-3640.  | 7.0 | 11        |
| 114 | EGFR mediates activation of RET in lung adenocarcinoma with neuroendocrine differentiation characterized by ASCL1 expression. <i>Oncotarget</i> , 2017, 8, 27155-27165.   | 1.8 | 11        |
| 115 | Tumor Junction Burden and Antigen Presentation as Predictors of Survival in Mesothelioma Treated With Immune Checkpoint Inhibitors. <i>Journal of Thoracic Oncology</i> , 2021, , .   | 1.1 | 11        |
| 116 | Cell-Free Tumor DNA Dominant Clone Allele Frequency Is Associated With Poor Outcomes in Advanced Biliary Cancers Treated With Platinum-Based Chemotherapy. <i>JCO Precision Oncology</i> , 2022, , .  | 3.0 | 11        |
| 117 | OA13.07 Intrapleural Modified Vaccine Strain Measles Virus Therapy for Patients with Malignant Pleural Mesothelioma. <i>Journal of Thoracic Oncology</i> , 2017, 12, S296.  | 1.1 | 10        |
| 118 | Utilization Trends and Factors Associated With ROS1 Testing Among Patients With Advanced Nonâ€“small-cell Lung Cancer in US Community Practices. <i>Clinical Lung Cancer</i> , 2021, 22, e470-e480.   | 2.6 | 10        |
| 119 | FDG-PET parameters as predictors of pathologic response and nodal clearance in patients with stage III non-small cell lung cancer receiving neoadjuvant chemoradiation and surgery. <i>Practical Radiation Oncology</i> , 2017, 7, e531-e541. | 2.1 | 9         |
| 120 | Human leukocyte antigen expression in paired primary lung tumors and brain metastases in non-small cell lung cancer. <i>Cancer Immunology, Immunotherapy</i> , 2021, 70, 215-219.   | 4.2 | 9         |
| 121 | Ablative radiotherapy for ultracentral lung cancers: Dosimetric, geometric, and volumetric predictors of outcomes and toxicity. <i>Radiotherapy and Oncology</i> , 2021, 158, 246-252.  | 0.6 | 9         |
| 122 | Synergy of cancer immunotherapy and radiotherapy. <i>Aging</i> , 2015, 7, 144-145.  | 3.1 | 9         |
| 123 | Reflections on immune checkpoint inhibition in non-small cell lung cancer. <i>Translational Lung Cancer Research</i> , 2014, 3, 411-3.  | 2.8 | 9         |
| 124 | First-line nivolumab plus ipilimumab versus chemotherapy for the treatment of unresectable malignant pleural mesothelioma: patient-reported outcomes in CheckMate 743. <i>Lung Cancer</i> , 2022, 167, 8-16.                                  | 2.0 | 9         |
| 125 | Immune checkpoint inhibition in malignant mesothelioma: Does it have a future?. <i>Lung Cancer</i> , 2017, 105, 49-51.  | 2.0 | 8         |
| 126 | Pathologic Considerations and Standardization in Mesothelioma Clinical Trials. <i>Journal of Thoracic Oncology</i> , 2019, 14, 1704-1717.   | 1.1 | 8         |



| #   | ARTICLE   | IF  | CITATIONS |
|-----|---|-----|-----------|
| 127 | An organ system-based approach to prognosis in advanced melanoma. <i>Frontiers in Bioscience - Elite</i> , 2012, E4, 2723-2733.   | 1.8 | 8         |
| 128 | Repurposing Ceritinib Induces DNA Damage and Enhances PARP Inhibitor Responses in High-Grade Serous Ovarian Carcinoma. <i>Cancer Research</i> , 2022, 82, 307-319.  | 0.9 | 8         |
| 129 | The dynamic human immune response to cancer: it might just be rocket science. <i>Immunotherapy</i> , 2011, 3, 1021-1024.  | 2.0 | 7         |
| 130 | Effect of Î²-Adrenergic Blockers and Other Antihypertensive Drugs on the Risk of Melanoma Recurrence and Deathâ€”I. <i>Mayo Clinic Proceedings</i> , 2014, 89, 1164-1165.   | 3.0 | 7         |
| 131 | A proof-of-concept trial of protein kinase C Î± inhibition with auranofin for the paclitaxel-induced acute pain syndrome. <i>Supportive Care in Cancer</i> , 2017, 25, 833-838.   | 2.2 | 7         |
| 132 | Nivo-lution in Mesothelioma. <i>Clinical Cancer Research</i> , 2019, 25, 5438-5440.   | 7.0 | 7         |
| 133 | ATOMIC-Meso: A randomized phase 2/3 trial of ADI-PEG20 or placebo with pemetrexed and cisplatin in patients with argininosuccinate synthetase 1-deficient non-epithelioid mesothelioma.. <i>Journal of Clinical Oncology</i> , 2017, 35, TPS8582-TPS8582. | 1.6 | 7         |
| 134 | Correlation of Somatostatin Receptor 2 Expression, 68Ga-DOTATATE PET Scan and Octreotide Treatment in Thymic Epithelial Tumors. <i>Frontiers in Oncology</i> , 2022, 12, 823667.  | 2.8 | 7         |
| 135 | Spontaneous Regression of Malignant Pleural Mesothelioma in a Patient with New-Onset Inflammatory Arthropathy. <i>Annals of the American Thoracic Society</i> , 2015, 12, 1416-1417.  | 3.2 | 6         |
| 136 | BCL-2-interacting mediator of cell death (Bim) is a novel biomarker for response to anti-PD-1 therapy in patients with advanced melanoma. <i>Immunotherapy</i> , 2016, 8, 1351-1353.  | 2.0 | 6         |
| 137 | Identification, Prioritization, and Treatment of Mutations Identified by Next-Generation Sequencing. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2018, 38, 873-880.              | 3.8 | 6         |
| 138 | Effects of Reduction in Tumor Burden on Survival in Epithelioid Malignant Pleural Mesothelioma. <i>Mayo Clinic Proceedings</i> , 2018, 93, 1026-1033.   | 3.0 | 6         |
| 139 | Heterogeneity of programmed deathâ€“ligand 1 expression in thymic epithelial tumours between initial specimen and synchronous or metachronous metastases or recurrences. <i>Histopathology</i> , 2019, 74, 364-367.                                       | 2.9 | 6         |
| 140 | Synergistic combination of cytotoxic chemotherapy and cyclinâ€“dependent kinase 4/6 inhibitors in biliary tract cancers. <i>Hepatology</i> , 2022, 75, 43-58.   | 7.3 | 6         |
| 141 | Detecting and Filtering Immune-Related Adverse Events Signal Based on Text Mining and Observational Health Data Sciences and Informatics Common Data Model: Framework Development Study. <i>JMIR Medical Informatics</i> , 2020, 8, e17353.               | 2.6 | 6         |
| 142 | Lower Exome Sequencing Coverage of Ancestrally African Patients in The Cancer Genome Atlas. <i>Journal of the National Cancer Institute</i> , 2022, 114, 1192-1199.   | 6.3 | 6         |
| 143 | The Predictive and Prognostic Nature of Programmed Death-Ligand 1 in Malignant Pleural Mesothelioma: A Systematic Literature Review. <i>JTO Clinical and Research Reports</i> , 2022, 3, 100315.  | 1.1 | 6         |
| 144 | Exploring the safety, effect on the tumor microenvironment, and efficacy of itacitinib in combination with epacadostat or pascalisib in advanced solid tumors: a phase I study. , 2022, 10, e004223.  |     | 6         |

| #   | ARTICLE   | IF   | CITATIONS |
|-----|---|------|-----------|
| 145 | Inhibition of Angiogenesis for the Treatment of Metastatic Melanoma. <i>Current Oncology Reports</i> , 2013, 15, 492-499.   | 4.0  | 5         |
| 146 | Loss of ATRX expression predicts worse prognosis in pulmonary carcinoid tumors. <i>Human Pathology</i> , 2019, 94, 78-85.   | 2.0  | 5         |
| 147 | Correlation of novel ALK ATI with ALK immunohistochemistry and clinical outcomes in metastatic melanoma. <i>Histopathology</i> , 2020, 77, 601-610.   | 2.9  | 5         |
| 148 | 71-Year-Old Man With Chronic Kidney Failure and Sudden Change of Mental Status. <i>Mayo Clinic Proceedings</i> , 2009, 84, e5-e8.   | 3.0  | 4         |
| 149 | Molecular Modeling and Functional Analysis of Exome Sequencingâ€Derived Variants of Unknown Significance Identify a Novel, Constitutively Active FGFR2 Mutant in Cholangiocarcinoma. <i>JCO Precision Oncology</i> , 2017, 2017, 1-13.           | 3.0  | 4         |
| 150 | Optimizing clinical cytology touch preparations for next generation sequencing. <i>Genomics</i> , 2020, 112, 5313-5323.   | 2.9  | 4         |
| 151 | FGFR2-IIIb Expression by Immunohistochemistry Has High Specificity in Cholangiocarcinoma with FGFR2 Genomic Alterations. <i>Digestive Diseases and Sciences</i> , 2022, 67, 3797-3805.  | 2.3  | 4         |
| 152 | Hydroxycarbamideâ€induced dermatopathy. <i>American Journal of Hematology</i> , 2010, 85, 75-76.   | 4.1  | 3         |
| 153 | Patan hospital experience in treating philadelphia chromosome/BCR-ABL1 positive chronic myeloid leukemia patients with gleevec (imatinib mesylate); the first generation specific tyrosine kinase inhibitor. <i>BMC Hematology</i> , 2010, 10, 8. | 2.6  | 3         |
| 154 | Towards a Molecular Classification of Pulmonary Sarcomatoid Carcinomas. <i>Journal of Thoracic Oncology</i> , 2017, 12, 910-912.  | 1.1  | 3         |
| 155 | Treating Philadelphia chromosome/BCR-ABL1 positive patients with Gleevec (Imatinib mesylate): 10-yearsâ€™ experience at Patan Hospital, Nepal. <i>British Journal of Haematology</i> , 2017, 177, 991-999.  | 2.5  | 3         |
| 156 | Targeting the Cardiotoxicity of Epidermal Growth Factor Receptor Inhibitors. <i>JACC: CardioOncology</i> , 2020, 2, 11-12.  | 4.0  | 3         |
| 157 | A phase 1 study of a novel inhibitor of protein phosphatase 2A alone and with docetaxel. <i>Journal of Clinical Oncology</i> , 2014, 32, TPS2636-TPS2636.   | 1.6  | 3         |
| 158 | Validating chemoimmunotherapy in small-cell lung cancer. <i>Lancet Oncology</i> , The, 2022, 23, 692-693.   | 10.7 | 3         |
| 159 | Severe hepatic dysfunction is associated with venous thromboembolic events in phase 1 clinical trials. <i>Thrombosis Research</i> , 2015, 136, 1169-1173.   | 1.7  | 2         |
| 160 | Radiotherapy for extensive stage small-cell lung cancer. <i>Lancet</i> , The, 2015, 385, 1291.  | 18.7 | 2         |
| 161 | 88P: Use of brain imaging in the management of patients with lymph node negative multifocal lung cancer. <i>Journal of Thoracic Oncology</i> , 2016, 11, S93-S94.   | 1.1  | 2         |
| 162 | Predictors of active cancer thromboembolic outcomes: validation of the Khorana score among patients with lung cancer: reply. <i>Journal of Thrombosis and Haemostasis</i> , 2017, 15, 591-592.  | 3.8  | 2         |

| #   | ARTICLE  | IF  | CITATIONS |
|-----|--|-----|-----------|
| 163 | Heterogeneity of PD-L1 expression between invasive and lepidic components of lung adenocarcinomas. <i>Cancer Immunology, Immunotherapy</i> , 2021, 70, 2651-2656.  | 4.2 | 2         |
| 164 | 68-Year-Old Man With Neutropenic Fever and Upper Extremity Hematoma. <i>Mayo Clinic Proceedings</i> , 2012, 87, 1226-1229.   | 3.0 | 1         |
| 165 | Predictors of relapse and evaluation of the role of postoperative radiation therapy in a modern series of patients with surgically resected stage III (N2) nonâ€small cell lung cancer. <i>Advances in Radiation Oncology</i> , 2017, 2, 12-18. | 1.2 | 1         |
| 166 | Local and systemic immunity predict survival in patients with pulmonary sarcomatoid carcinoma. <i>Medical Oncology</i> , 2017, 34, 140.  | 2.5 | 1         |
| 167 | Predictors of active cancer thromboembolic outcomes: role of body composition. <i>International Angiology</i> , 2017, 36, 88-89.   | 0.9 | 1         |
| 168 | Multifocal Pulmonary Adenocarcinoma with Ground-Glass/Lepidic Featuresâ€Exciting Times as the Mystery Is Unfolding. <i>Journal of Thoracic Oncology</i> , 2018, 13, 1616-1618.  | 1.1 | 1         |
| 169 | Predicting Treatment Response Based on RNA Expression in Large Datasets. <i>Clinical Cancer Research</i> , 2019, 25, 1443-1445.  | 7.0 | 1         |
| 170 | SATB2 Is Expressed in a Subset of Pulmonary and Thymic Neuroendocrine Tumors. <i>American Journal of Clinical Pathology</i> , 2021, 156, 853-865.  | 0.7 | 1         |
| 171 | No Association of BRCA Mutations with Therapy-Related Myelodysplastic Syndrome or Acute Myeloid Leukemia in Patients Treated for Breast or Ovarian Cancer. <i>Blood</i> , 2011, 118, 4259-4259.  | 1.4 | 1         |
| 172 | Checkpoint Blockade in Unresectable Pleural Mesothelioma: Event Horizon for Multimodal Therapy. <i>Journal of Thoracic and Cardiovascular Surgery</i> , 2022, , .  | 0.8 | 1         |
| 173 | The Evolving Therapeutic Landscape for Malignant Pleural Mesothelioma. <i>Current Oncology Reports</i> , 2022, 24, 1413-1423.  | 4.0 | 1         |
| 174 | Primary venous thromboembolism prophylaxis in patients with solid tumors. <i>Journal of Thrombosis and Thrombolysis</i> , 2015, 39, 258-259.   | 2.1 | 0         |
| 175 | Rapidly Appearing Sclerotic Vertebral Lesions in a Patient With an Infiltrative Mediastinal Mass. <i>JAMA Oncology</i> , 2016, 2, 267.   | 7.1 | 0         |
| 176 | Significance of Immune Checkpoints in Lung Cancer. , 2018, , 59-77.  |     | 0         |
| 177 | 9. Detection of fusion genes from complex rearrangements reported by genome-wide mate-pair sequencing (MPseq). <i>Cancer Genetics</i> , 2018, 224-225, 53-54.  | 0.4 | 0         |
| 178 | Maintaining Equipoise With Maintenance Therapy inÂMesothelioma. <i>Clinical Lung Cancer</i> , 2020, 21, 482-484.   | 2.6 | 0         |
| 179 | Surgery for Mesothelioma After Radiation Therapy (SMART); A Single Institution Experience. <i>Frontiers in Oncology</i> , 2020, 10, 392.   | 2.8 | 0         |
| 180 | A novel method for identifying downstream signals in tumor-reactive T cells following PD-1 engagement and monitoring endogenous tumor immunity and immunotherapy.. <i>Journal of Clinical Oncology</i> , 2014, 32, 3049-3049.                    | 1.6 | 0         |

| #   | ARTICLE   | IF  | CITATIONS |
|-----|---|-----|-----------|
| 181 | The Mayo Clinic experience with the use of kinase inhibitors (KIs), ipilimumab, and bevacizumab in the treatment of metastatic ocular melanoma.. Journal of Clinical Oncology, 2014, 32, e20011-e20011. | 1.6 | 0         |
| 182 | Association of early venous thromboembolic events with worse prognosis in patients with lung cancer.. Journal of Clinical Oncology, 2014, 32, e20623-e20623.  | 1.6 | 0         |
| 183 | Is durvalumab the solution for unresectable stage III non-small cell lung cancer?. Translational Cancer Research, 2018, 7, S89-S93.   | 1.0 | 0         |
| 184 | Understanding Clinical Trials in Malignant Mesothelioma. , 2019, , 187-202.   |     | 0         |
| 185 | Abstract A120: Sex differences in tolerability and response to immune checkpoint inhibitors in non-small cell lung cancer patients. , 2020, , .   |     | 0         |
| 186 | Trials, tribunals, and opportunities for lung cancer KRASG12C brain metastases. Clinical Cancer Research, 0, , .  | 7.0 | 0         |
| 187 | Response to Mittr and Pollack. Journal of the National Cancer Institute, 0, , .   | 6.3 | 0         |